-

SHAREHOLDER NOTIFICATION: Kaskela Law LLC Announces Investigation of Instructure Holdings, Inc. (NYSE: INST) Buyout and Encourages Investors to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating the recently announced proposed buyout of Instructure Holdings, Inc. (NYSE: INST) (“Instructure”) shareholders on behalf of the company’s investors.

On July 25, 2024, Instructure announced that it had agreed to be acquired by private equity firm KKR at a price of $23.60 per share – a premium of just $0.87 per share, or less than 4%, to the stock’s prior day closing price of $22.73. Following the closing of the proposed transaction, Instructure’s shareholders will be cashed out of their investment position and the company’s shares will no longer be publicly traded.

The investigation thus far has revealed that the process leading up to the announcement of the buyout appears to have significant conflicts of interest, thus making the sales process as well as the price-per-share appear unfair to the company’s shareholders. Notably, just one week prior to the announcement of the shareholder buyout, shares of the company’s stock traded at prices above $25.00 per share, and numerous analysts were maintaining price targets for INST shares in excess of $30.00 per share.

Instructure shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional information about this investigation and their legal rights and options at (484) 229 – 0750, or by clicking on the following link (or if necessary, by copying and pasting the link into your browser):

https://kaskelalaw.com/case/instructure-holdings/

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.

This notice may constitute attorney advertising in certain jurisdictions.

Contacts

KASKELA LAW LLC
D. Seamus Kaskela, Esq.
(skaskela@kaskelalaw.com)
Adrienne Bell, Esq.
(abell@kaskelalaw.com)
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 – 1740
(484) 229 – 0750
www.kaskelalaw.com

Kaskela Law LLC

NYSE:INST

Release Versions

Contacts

KASKELA LAW LLC
D. Seamus Kaskela, Esq.
(skaskela@kaskelalaw.com)
Adrienne Bell, Esq.
(abell@kaskelalaw.com)
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 – 1740
(484) 229 – 0750
www.kaskelalaw.com

More News From Kaskela Law LLC

Kaskela Law Firm Reports Ongoing Shareholder Investigation of Reservoir Media, Inc. and Encourages Investors to Contact the Firm – RSVR

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law is investigating Reservoir Media, Inc. (NASDAQ: RSVR) on behalf of the company's shareholders....

Kaskela Law Firm Reports Ongoing Shareholder Investigation of Priority Technology Holdings, Inc. and Encourages Investors to Contact the Firm – PRTH

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC is conducting a stockholder investigation into Priority Technology Holdings, Inc. (NASDAQ: PRTH) (“Priority Technology”). The investigation seeks to determine whether Priority Technology and/or the company’s representatives violated the securities laws or breached their fiduciary duties in connection with recent corporate actions. Priority Technology shareholders should contact Kaskela Law (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 2...

SELECT MEDICAL STOCK ALERT: Does $16.50 Per Share Represent a Fair Shareholder Buyout Price? Kaskela Law Firm Announces Investigation into Fairness of Buyout Offer and Encourages Investors to Contact the Firm – SEM

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC is investigating the recently announced buyout of Select Medical Holdings Corp. (“Select Medical”) (NYSE: SEM) shareholders to determine whether the $16.50 per share buyout offer is fair to the company’s investors or if it undervalues the company’s shares. Click here for additional information: https://kaskelalaw.com/case/select-medical/ On March 2, 2026, Select Medical announced that it had agreed to be acquired by an investment consortium at a pr...
Back to Newsroom